Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

PULSE BIOSCIENCES, INC. (PLSE)

$30.23 -2.48% NASDAQ: PLSE · 15-min delayed
  • HAYWARD, California
  • Public · NASDAQ: PLSE
  • 116 employees
$1.8BMarket cap
$350.0KRevenue · FY2025
-$72.8MNet income
116Employees
PLSENASDAQ
2016IPO

About PULSE BIOSCIENCES, INC.

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$350.0K
Net income
-$72.8M
Total assets
$94.5M
Market cap
$1.8B
Gross margin
-54.0%
Operating margin
-21982.6%
Net margin
-20794.6%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$350.0K
Cost of revenue
$539.0K
Gross profit
-$189.0K
Operating expenses
$76.8M
Operating income
-$76.9M
Income tax
$0
Net income
-$72.8M
EPS (basic)
$-1.08

Balance sheet

Total assets
$94.5M
Current assets
$83.4M
Total liabilities
$13.9M
Current liabilities
$7.9M
Shareholders’ equity
$80.7M

Cash flow

Operating cash flow
-$54.1M
Investing cash flow
-$335.0K
Financing cash flow
$17.2M
Net cash flow
-$37.3M

Statements via Polygon.io (SEC filings)

NASDAQ: PLSE
$30.23 -2.48%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$12.66 $32.76

52-week range

Market cap
$1.8B
Shares outstanding
58.0M
Open
Day range
Prev close
Volume
IPO date
May 18, 2016

Pulse Biosciences, Inc. (PLSE) Stock Price

  • Reported a net loss of $72.8M in FY2025.
  • Revenue declined 75% from FY2021 to FY2025.
  • Gross margin of -54.0%, net margin -20794.6%.
  • Trading 8% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review PULSE BIOSCIENCES, INC..

Write a review
Newsroom

News about PULSE BIOSCIENCES, INC.

News & sentiment via Polygon.io

FAQ

Pulse Biosciences, Inc.: frequently asked questions

Is Pulse Biosciences, Inc. an American company?

Pulse Biosciences, Inc. is a US-based company headquartered in Hayward, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Pulse Biosciences, Inc. headquartered?

Pulse Biosciences, Inc. is headquartered in Hayward, California, United States.

Is Pulse Biosciences, Inc. publicly traded?

Yes — Pulse Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol PLSE on the NASDAQ.

What does Pulse Biosciences, Inc. do?

Pulse Biosciences, Inc. is an American Medical Devices company in the Health & Beauty sector.

Explore

Similar companies

Browse all →